Take the challenge. CPT: 20611-LT, J7325-EJ ICD-10: M17.12, E66.01, Z68.41 CPT: 99213 ICD-10: M1a.0710, M05.79 History—The history of present illness was extended. The review of systems was extended, and two past family social history elements were documented. This makes the history level detailed. Examination—Five systems were examined. This makes the exam level detailed. Medical decision…
Search results for: gout
Canakinumab Reduces Risk for Gout Flares, But Not Serum Uric Acid Levels
An exploratory analysis of a canakinumab clinical trial has shown the interleukin 1β inhibitor may significantly reduce patients’ risk for gout flares. During the study, patients using canakinumab experienced this decreased risk, but the treatment did not change serum uric acid levels…
Older Gout Patients More Likely to Develop Hearing Impairment
Previous research has established that gout and hearing loss have shared risk factors. Now, a recent study found gout itself is associated with an increased risk of hearing loss in adults 65 years and older…
Allopurinol for Gout an Unlikely Contributor to Kidney Disease
NEW YORK (Reuters Health)—Allopurinol does not appear to contribute to decline in kidney function and may actually protect renal function in patients with gout, according to a large population-based study. Gout affects around 4% of Americans and often occurs alongside chronic kidney disease (CKD), Dr. Tuhina Neogi from Boston University School of Medicine and colleagues…
5 Takeaways from the ACR’s Gout Clinical Quality Measures
With electronic clinical quality measures tailored for treating gout patients, physicians and their teams now have tools to measure and improve gout care performance and outcomes…
Gout Emergency Department Visits Up
In the past nine years, visits to the emergency department by gout patients have increased by almost 27%. Researchers suggest physicians may not adequately be addressing the burden of gout and the underlying accumulation of uric acid, driving the dramatic increase in emergency department visits in the U.S…
New Study Raises Cardiovascular Questions about Febuxostat for Gout
New research raises questions about the cardiovascular safety of febuxostat for gout patients compared with allopurinol. The study found that although febuxostat was noninferior to allopurinol, febuxostat-treated patients had similar overall rates of major adverse cardiovascular events as allopurinol-treated patients, but had higher rates of all-cause mortality and cardiovascular mortality…
Pathophysiology of Gouty Tophi
In a recent study, researchers examined synovial fluid and non-inflamed tophi from the acutely inflamed joints of patients with gout, finding that monosodium urate (MSU) crystals trigger a distinct physiological NETosis pathway that coats MSU crystals in DNA that persists in tissues as gouty tophi…
Study Finds Newer Gout Drug Poses Risk to Heart Patients
(Reuters Health)—Gout sufferers with major pre-existing heart disease face a higher risk of death if they are treated with the drug febuxostat, a large long-term study has concluded. The risk of death from cardiovascular disease was 34% higher with febuxostat than with allopurinol. When researchers considered deaths from any cause, the risk was 22% higher…
Patients with Gout May Be More Likely to Develop Osteoporosis
NEW YORK (Reuters Health)—People with gout face a modestly increased risk, of about 20%, for developing osteoporosis, compared to people without gout, researchers in Taiwan suggest. In their population-based study to examine a possible association between gout and subsequent osteoporosis, Dr. Victor C. Kok of Asia University (Taiwan), Taichung, and colleagues retrospectively analyzed data from…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 59
- Next Page »